Category Press Releases

WuXi Biologics, VISEN Partner to Make Lonapegsomatropin in Chengdu

WuXi Biologics and VISEN Pharmaceuticals Expand Partnership to Localize Production of Lonapegsomatropin in China WuXi Biologics ,a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO) services, and VISEN Pharmaceuticals (HKEX: 2561), a clinical-stage biopharmaceutical company dedicated to advancing…

Read MoreWuXi Biologics, VISEN Partner to Make Lonapegsomatropin in Chengdu

WHO Unveils Online Training Series to Support Chemical Emergency Preparedness

WHO Advances Global Chemical Hazard Preparedness with New Comprehensive Online Training Series In a recent address to the Seventy-eighth World Health Assembly, Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), brought critical attention to an often-overlooked public…

Read MoreWHO Unveils Online Training Series to Support Chemical Emergency Preparedness

Lilly Unveils First Clinical Data for Next-Gen FRα ADC in Platinum-Resistant Ovarian Cancer at ASCO 2025

Eli Lilly Presents Promising Phase 1 Data for Investigational FRα-Targeting ADC in Platinum-Resistant Ovarian Cancer at ASCO 2025 Eli Lilly and Company has announced encouraging new Phase 1 clinical data for its investigational folate receptor alpha (FRα) targeting antibody-drug conjugate…

Read MoreLilly Unveils First Clinical Data for Next-Gen FRα ADC in Platinum-Resistant Ovarian Cancer at ASCO 2025

Protagonist & Takeda to Present Full 32-Week Phase 3 VERIFY Results on Rusfertide at ASCO

Protagonist Therapeutics and Takeda Reveal Comprehensive Phase 3 VERIFY Study Results for Rusfertide in Polycythemia Vera at ASCO 2025 Protagonist Therapeutics,and Takeda Pharmaceutical Company Limited have announced detailed findings from the Phase 3 VERIFY clinical trial evaluating rusfertide, an investigational…

Read MoreProtagonist & Takeda to Present Full 32-Week Phase 3 VERIFY Results on Rusfertide at ASCO

AskBio Publishes Full Phase 1b Results of AB-1005 Gene Therapy for Parkinson’s Disease

AskBio Publishes Complete Phase 1b Trial Results of AB-1005 Gene Therapy for Parkinson’s Disease in Leading Neurology Journal Asklepios BioPharmaceutical, Inc. (AskBio), a pioneering gene therapy company that operates as a wholly owned, independent subsidiary of the global pharmaceutical giant…

Read MoreAskBio Publishes Full Phase 1b Results of AB-1005 Gene Therapy for Parkinson’s Disease